ROCKVILLE, Md.— New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past ...

Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4 toxicities at doses as low as 5 mg BID Initiating an ...